|
GB8712540D0
(en)
|
1987-05-28 |
1987-07-01 |
Ucb Sa |
Expression of human proapolipoprotein a-i
|
|
US5220043A
(en)
|
1991-03-21 |
1993-06-15 |
Ohio University |
Synthesis of D-erythro-sphingomyelins
|
|
SE9103701D0
(sv)
|
1991-12-13 |
1991-12-13 |
Kabi Pharmacia Ab |
Apolipoprotein
|
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
SE9203753D0
(sv)
|
1992-12-11 |
1992-12-11 |
Kabi Pharmacia Ab |
Expression system for producing apolipoprotein ai-m
|
|
FR2704556B1
(fr)
|
1993-04-30 |
1995-07-13 |
Rhone Poulenc Rorer Sa |
Virus recombinants et leur utilisation en thérapie génique.
|
|
EP0751961A1
(en)
|
1994-03-22 |
1997-01-08 |
Research Corporation Technologies, Inc. |
Eating suppressant peptides
|
|
US5932536A
(en)
|
1994-06-14 |
1999-08-03 |
The Rockefeller University |
Compositions for neutralization of lipopolysaccharides
|
|
SE9500778D0
(sv)
|
1995-03-03 |
1995-03-03 |
Pharmacia Ab |
Process for producing a protein
|
|
US5648387A
(en)
|
1995-03-24 |
1997-07-15 |
Warner-Lambert Company |
Carboxyalkylethers, formulations, and treatment of vascular diseases
|
|
US6258596B1
(en)
|
1995-05-22 |
2001-07-10 |
Aventis Pharmaceuticals Products Inc. |
Variants of apolipoprotein A-I
|
|
GB9526733D0
(en)
|
1995-12-30 |
1996-02-28 |
Delta Biotechnology Ltd |
Fusion proteins
|
|
SE9603068D0
(sv)
|
1996-08-23 |
1996-08-23 |
Pharmacia & Upjohn Ab |
Process for purifying a protein
|
|
SE9603303D0
(sv)
|
1996-09-11 |
1996-09-11 |
Pharmacia & Upjohn Ab |
Process for purifying a protein
|
|
SE9603304D0
(sv)
|
1996-09-11 |
1996-09-11 |
Pharmacia & Upjohn Ab |
Process for purifying a compound
|
|
US6306433B1
(en)
|
1997-08-12 |
2001-10-23 |
Pharmacia Ab |
Method of preparing pharmaceutical compositions
|
|
US6004925A
(en)
|
1997-09-29 |
1999-12-21 |
J. L. Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6037323A
(en)
|
1997-09-29 |
2000-03-14 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6518412B1
(en)
|
1997-09-29 |
2003-02-11 |
Jean-Louis Dasseux |
Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6046166A
(en)
|
1997-09-29 |
2000-04-04 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6287590B1
(en)
|
1997-10-02 |
2001-09-11 |
Esperion Therapeutics, Inc. |
Peptide/lipid complex formation by co-lyophilization
|
|
CA2356704A1
(en)
|
1998-12-30 |
2000-07-13 |
Folke Tjerneld |
Separation method utilizing liquid-liquid partition
|
|
US6459003B1
(en)
|
1999-04-01 |
2002-10-01 |
Esperion Therapeutics, Inc. |
Ether compounds
|
|
GB9919713D0
(en)
|
1999-08-19 |
1999-10-20 |
Queen Mary & Westfield College |
New medical use of high density lipoprotein
|
|
US6926898B2
(en)
|
2000-04-12 |
2005-08-09 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US6946134B1
(en)
|
2000-04-12 |
2005-09-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
DK1290013T3
(da)
|
2000-04-21 |
2006-06-26 |
Amgen Inc |
Apo-A1/All-peptidderivater
|
|
US6664230B1
(en)
|
2000-08-24 |
2003-12-16 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
US7148197B2
(en)
|
2000-08-24 |
2006-12-12 |
The Regents Of The University Of California |
Orally administered small peptides synergize statin activity
|
|
US7723303B2
(en)
|
2000-08-24 |
2010-05-25 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
|
US7144862B2
(en)
|
2000-08-24 |
2006-12-05 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
|
US7166578B2
(en)
|
2000-08-24 |
2007-01-23 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
|
US7199102B2
(en)
|
2000-08-24 |
2007-04-03 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
|
CN1962596A
(zh)
|
2000-10-11 |
2007-05-16 |
埃斯佩里安医疗公司 |
用于控制胆固醇以及相关用途的酮化合物以及组合物
|
|
WO2002030884A2
(en)
|
2000-10-11 |
2002-04-18 |
Esperion Therapeutics, Inc. |
Sulfide and disulfide compounds and compositions for cholesterol management and related uses
|
|
US7304093B2
(en)
|
2000-10-11 |
2007-12-04 |
Esperion Therapeutics, Inc. |
Ketone compounds and compositions for cholesterol management and related uses
|
|
MXPA03003021A
(es)
|
2000-10-11 |
2003-07-14 |
Esperion Therapeutics Inc |
Compuestos de eter y composiciones para el control del colesterol y usos relacionados.
|
|
JP2004531459A
(ja)
|
2000-10-11 |
2004-10-14 |
エスペリオン セラピューティクス，インコーポレイテッド |
コレステロールマネージメント用スルホキシドおよびビススルホキシド化合物ならびに組成物および関連する使用
|
|
WO2002038609A2
(en)
|
2000-11-10 |
2002-05-16 |
Proteopharma Aps |
Apolipoprotein conjugates
|
|
US7507413B2
(en)
|
2001-04-12 |
2009-03-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US7217785B2
(en)
|
2001-05-09 |
2007-05-15 |
The Regents Of The University Of California |
Cysteine-containing peptides having antioxidant properties
|
|
WO2003000381A1
(en)
|
2001-06-25 |
2003-01-03 |
Lipid Sciences, Inc. |
Hollow fiber contactor systems for removal of lipids from fluids
|
|
US6991727B2
(en)
|
2001-06-25 |
2006-01-31 |
Lipid Sciences, Inc. |
Hollow fiber contactor systems for removal of lipids from fluids
|
|
US20060060520A1
(en)
|
2001-06-25 |
2006-03-23 |
Bomberger David C |
Systems and methods using a solvent for the removal of lipids from fluids
|
|
ES2304452T3
(es)
|
2001-08-20 |
2008-10-16 |
Csl Behring Ag |
Una hdl para el tratamiento de un ictus y de otras condiciones isquemicas.
|
|
AUPR798901A0
(en)
|
2001-09-28 |
2001-10-25 |
Medvet Science Pty. Ltd. |
Spheroidal hdl particles with a defined phospholipid composition
|
|
NZ532217A
(en)
|
2001-09-28 |
2006-12-22 |
Esperion Therapeutics Inc |
Use of an alpha helical apolipoprotein or HDL associating protein adapted to be administered locally to prevent or reduce stenosis or restenosis or to stabilize a plaque
|
|
CA2841097A1
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin and g-csf fusion proteins
|
|
WO2005003296A2
(en)
|
2003-01-22 |
2005-01-13 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US7223726B2
(en)
|
2002-01-14 |
2007-05-29 |
The Regents Of The University Of California |
Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
|
|
US6930085B2
(en)
|
2002-04-05 |
2005-08-16 |
The Regents Of The University Of California |
G-type peptides to ameliorate atherosclerosis
|
|
MXPA04011312A
(es)
|
2002-05-17 |
2005-02-14 |
Esperion Therapeutics Inc |
Metodo para el tratamiento de desordenes dislipidemicos.
|
|
US6953840B2
(en)
|
2002-07-30 |
2005-10-11 |
Esperion Therapeutics, Inc. |
Methods of using non-human animal Apolipoprotein A-I protein
|
|
US7335689B2
(en)
|
2003-01-23 |
2008-02-26 |
Esperion Therapeutics, Inc. |
Dihydroxyl compounds and compositions for cholesterol management and related uses
|
|
JP2007527387A
(ja)
|
2003-07-03 |
2007-09-27 |
リピッド サイエンシーズ，インコーポレイテッド |
脂質含量の低下したｈｄｌの粒子誘導体を製造するための方法及び装置
|
|
US7393826B2
(en)
|
2003-07-03 |
2008-07-01 |
Lipid Sciences, Inc. |
Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
|
|
US7390504B2
(en)
|
2003-11-07 |
2008-06-24 |
Jj Pharma, Inc. |
HDL-boosting combination therapy complexes
|
|
TW200526778A
(en)
|
2003-11-14 |
2005-08-16 |
Sembiosys Genetics Inc |
Methods for the production of apolipoproteins in transgenic plants
|
|
AU2004296829A1
(en)
|
2003-12-05 |
2005-06-23 |
The Cleveland Clinic Foundation |
Risk markers for cardiovascular disease
|
|
EP1706131A4
(en)
|
2003-12-15 |
2009-08-12 |
Univ California |
THE CELLULAR CHOLESTEROL EFFLUX STIMULATING HELICULAR SYNTHETIC PEPTIDES
|
|
US7705177B2
(en)
|
2003-12-24 |
2010-04-27 |
Esperion Therapuetics, Inc. |
Ketone compounds and compositions for cholesterol management and related uses
|
|
KR100560102B1
(ko)
|
2004-06-25 |
2006-03-13 |
한국생명공학연구원 |
프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
|
|
US7378396B2
(en)
|
2004-08-11 |
2008-05-27 |
The Cleveland Clinic Foundation |
Therapeutic agents and methods for cardiovascular disease
|
|
EP2218736A1
(en)
|
2004-10-15 |
2010-08-18 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Implant coated with multi-domain amphipathic helical peptides and methods of their use
|
|
US8206750B2
(en)
|
2005-03-24 |
2012-06-26 |
Cerenis Therapeutics Holding S.A. |
Charged lipoprotein complexes and their uses
|
|
ES2402823T3
(es)
|
2006-06-01 |
2013-05-09 |
Institut De Cardiologie De Montreal |
Compuesto para uso en el tratamiento de estenosis valvular
|
|
EP2049137A4
(en)
|
2006-08-08 |
2013-05-01 |
Univ California |
SALICYLANILIDES AS AMPLIFIERS OF THE ORAL RELEASE OF THERAPEUTIC PEPTIDES
|
|
US8541236B2
(en)
|
2006-12-08 |
2013-09-24 |
University Of Washington |
Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
|
|
PT2118074E
(pt)
|
2007-02-01 |
2014-03-20 |
Resverlogix Corp |
Compostos para a prevenção e tratamento de doenças cardiovasculares
|
|
US7956035B2
(en)
|
2007-03-01 |
2011-06-07 |
Csl Limited |
Treatment of endothelial dysfunction in diabetic patients
|
|
US7749315B2
(en)
|
2007-04-04 |
2010-07-06 |
Xerox Corporation |
Phase change inks containing colorant compounds
|
|
NZ582170A
(en)
|
2007-08-17 |
2012-02-24 |
Csl Behring Gmbh |
Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i
|
|
AU2008296487A1
(en)
|
2007-08-28 |
2009-03-12 |
The Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
|
US8101565B2
(en)
|
2007-09-20 |
2012-01-24 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US7985727B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Apo A-I mimetic peptides and methods of treatment
|
|
US7985728B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US8044021B2
(en)
|
2007-09-20 |
2011-10-25 |
Abbott Cardiovascular Systems Inc. |
Sustained release of apo A-I mimetic peptides and methods of treatment
|
|
EP2207800A1
(en)
|
2007-10-19 |
2010-07-21 |
Pronota NV |
A protease-sensitive site in apolipoprotein a1, therapeutic and diagnostic implications
|
|
ES2601830T3
(es)
|
2007-10-23 |
2017-02-16 |
The Cleveland Clinic Foundation |
Apolipoproteína A-1 resistente a oxidantes y péptidos miméticos
|
|
CN102123722A
(zh)
|
2008-06-18 |
2011-07-13 |
加利福尼亚大学董事会 |
改进的胆固醇流出的肽介质
|
|
MX2011008599A
(es)
|
2009-02-16 |
2011-11-18 |
Cerenis Therapeutics Sa |
Peptidos mimeticos de la apolipoproteina a-i.
|
|
KR20220038506A
(ko)
|
2009-06-10 |
2022-03-28 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
|
US20110152112A1
(en)
*
|
2009-12-23 |
2011-06-23 |
Artery Therapeutics, Inc. |
Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases
|
|
EP3492085A1
(en)
|
2010-06-30 |
2019-06-05 |
CSL Limited |
A reconstituted high density lipoprotein formulation and production method therof
|
|
LT2673296T
(lt)
|
2011-02-07 |
2019-02-25 |
Cerenis Therapeutics Holding Sa |
Lipoproteino kompleksai ir jų gamyba ir jų panaudojimai
|